Batich, K. A., Staats, J. S., Chan, C., Krejsa, C., George, D. J., Weinhold, K. J., & Zhang, T. (2018). Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC). In Journal of Clinical Oncology (Vol. 36, pp. e16519–e16519). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.e16519

Batich, Kristen A., Janet S. Staats, Cliburn Chan, Cecile Krejsa, Daniel J. George, Kent J. Weinhold, and Tian Zhang. “Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 36:e16519–e16519. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e16519.

Batich KA, Staats JS, Chan C, Krejsa C, George DJ, Weinhold KJ, et al. Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. e16519–e16519.

Batich, Kristen A., et al. “Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. e16519–e16519. Crossref, doi:10.1200/jco.2018.36.15_suppl.e16519.

Batich KA, Staats JS, Chan C, Krejsa C, George DJ, Weinhold KJ, Zhang T. Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. e16519–e16519.